Australia's most trusted
source of pharma news
Wednesday, 17 June 2026
Posted 17 June 2026 PM
The TGA has issued a warning to health professionals after identifying 161 adverse event reports related to AstraZeneca’s FluMist just days after the NSW Government expanded funded access to the influenza nasal spray.
The new needle-free vaccine is indicated for the prevention of influenza in children and adolescents aged 24 months to less than 18 years.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.